Press release provided by the Society for Maternal Fetal Medicine
As more states legalize marijuana for recreational use, researchers are looking into the potential health effects of cannabis use during pregnancy.
In a new study presented today at the Society for Maternal-Fetal Medicine’s (SMFM) annual meeting, The Pregnancy Meeting™ — and published in the American Journal of Obstetrics & Gynecology — researchers unveiled findings that suggest that using cannabis in the first six to 14 weeks of pregnancy is associated with poor pregnancy outcomes that are closely related to the function of the placenta.
The placenta plays an important role during pregnancy, including providing an infant with oxygen and nutrients, removing harmful waste and carbon dioxide, and producing hormones that help a baby grow. Medicine, drugs, alcohol and nicotine can transfer from a pregnant person’s bloodstream to their baby through the placenta.
Researchers analyzed urine samples collected during the Nulliparous Mothers-to-Be (nuMoM2b) study, a large, diverse multicenter cohort of pregnant people. Of the 10,038 nuMoM2b participants, researchers included data from 9,257 pregnant people in their first trimester of pregnancy.
After doing a drug screen for marijuana, researchers discovered that 540 (5.8 percent) tested positive for marijuana, meaning those individuals most likely used cannabis in the first six to 14 weeks of their pregnancy. The study found that using cannabis early in pregnancy is associated with adverse pregnancy outcomes related to the placenta, such as poor fetal growth, stillbirth, and an increased risk of developing high blood pressure during pregnancy.
“We wanted to look specifically at cannabis use early in pregnancy because that’s when the placenta is forming, and a lot of information we currently have indicates that cannabis use does affect the placenta,” says the study’s lead author Torri D. Metz, MD, MS, a maternal-fetal medicine subspecialist and associate professor of obstetrics and gynecology at the University of Utah Health in Salt Lake City.
“With recreational marijuana use becoming legal in more states, we need better data because patients are interested in understanding the risk of cannabis use in pregnancy so they can make an informed decision.”
The next step, say researchers, is to look at ongoing cannabis use during pregnancy and whether “the window of exposure” matters.
To view the presentation of this abstract or other Pregnancy Meeting™ abstracts and events, visit the SMFM website.
About the Society for Maternal-Fetal Medicine
The Society for Maternal-Fetal Medicine (SMFM), founded in 1977, is the medical professional society for maternal-fetal medicine subspecialists, who are obstetricians with additional training in high-risk pregnancies. SMFM represents more than 5,500 members who care for high-risk pregnant people and provides education, promotes research, and engages in advocacy to advance optimal and equitable perinatal outcomes for all people who desire and experience pregnancy. For more information, visit SMFM.org and connect with the organization on Facebook and Twitter. For the latest 2023 Annual Meeting news and updates, follow the hashtag #smfm23.